Aurora Bioscience gains TGA approval for ViewSite™ Brain Access System (VBAS)

The ViewSite™ Brain Access System is a revolutionary approach in brain retraction.

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has achieved registration by the Therapeutics Good Administration (TGA) of Vycor Medical’s ViewSite™ Brain Access System or “VBAS”.

The ViewSite™ Brain Access System is a revolutionary approach in brain retraction. Each ViewSite system consists of an introducer and a working channel port that allows the surgeon a seamless entry to the targeted site while distributing brain tissue evenly in a 360° dispersion pattern. Other ViewSite benefits include superior binocular vision to see in and around the surgical site; multiple sizes in different widths and lengths to meet all surgical needs and compatibility with most surgical arms to avoid accidental displacement or movement during surgery.

Aurora BioScience entered into an exclusive distribution agreement with Vycor Medical (USA) in 2010; under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.

“Brain disease, whether it be cancer or vascular in origin, is a major cause of morbidity and mortality in Australia” said Darren Banks, Managing Director of Aurora BioScience. “We believe that the VBAS system, with its focus on minimising collateral trauma and improving visibility for the surgeon, could aid significantly in the surgical treatment of brain cancer and neurovascular procedures.”

The accessing of targeted brain tissue without unduly damaging surrounding tissue requires specialised instrumentation that is less invasive in performing critical procedures while minimising collateral trauma – resulting in accelerated postoperative recovery. 

The common instruments used in brain retraction procedures are ribbon or blade retractors; even though these instruments are still in use, neurosurgeons have a need for devices that provide better surgical outcomes – results that are beneficial to both the surgeon and the patient. New and quantifiable technologies such as Image Guided Surgery (IGS) is dependent upon the system recognising key components (i.e. retractors) and having them become a recognised portion of the system and the procedure, like the VBAS.

“We are excited to be partnering with such an innovative company as Vycor Medical and believe the VBAS system can have a significant impact of patient’s lives. We are expecting the first procedures to be undertaken in Australia in July with many institutions very keen to evaluate the product” stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include cancer therapies, neurology, pulmonology, haematology and blood products. For more information, please visit

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (VYCO.BB) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective.  The company’s flagship, patent pending ViewSite™ Surgical Access System (VBAS) represents an exciting new minimally invasive access and retraction system that holds the potential for speedier, safer and more economical brain, spinal and other surgeries.  Vycor’s VBAS offers the advantage of being able to be used in conjunction with neuronavigational systems to optimise neurosurgical site access, decrease the potential risks of the surgery, and minimise tissue manipulation, all of which should lead to enhanced patient outcome and possible earlier release from the hospital. Some surgeons have even noted the ability to perform procedures that might not have otherwise been accomplished.